ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

9:00AM-10:30AM: Abstract Number: 0670

A Short Allelic Epitope Coded by HLA-DRB1*03:01 Activates a Systemic Lupus Erythematosus Cell Aberration Cascade

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0874

A Tale of Many Canadas: Associations of Ethnicity with Juvenile Idiopathic Arthritis Categories and Disease Severity at Presentation in a Multicultural Universal Healthcare Setting: Results from ReACCh-Out

Pediatric Rheumatology – Clinical Poster I: JIA

9:00AM-10:30AM: Abstract Number: 0878

A United States Nationwide Analysis of Total Knee Arthroplasty in Patients < 21 Years Old

Pediatric Rheumatology – Clinical Poster I: JIA

9:00AM-10:30AM: Abstract Number: 0932

Accelerated Waning of Protective Immunity After SARS-CoV-2 mRNA Vaccination in Patients Treated with Biological and Targeted Synthetic Disease Modifying Antirheumatic Drugs

RA – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 0751

Accessing Telehealth and In-Person Healthcare During the COVID-19 Pandemic: Experiences of Individuals with Rheumatoid Arthritis

Health Services Research Poster II

9:00AM-10:30AM: Abstract Number: 0707

Accuracy of Administrative Claims Prescription Fill Data to Estimate Glucocorticoid Use and Dose in Patients with Rheumatoid Arthritis

Epidemiology and Public Health Poster I

9:00AM-10:30AM: Abstract Number: 0700

Accurate Identification of ANCA-Associated Vasculitis Cases from Clinical Notes Using Machine Learning

Epidemiology and Public Health Poster I

9:00AM-10:30AM: Abstract Number: 0773

Additional Dose of SARS-CoV-2 Vaccine Improves Cross-Variant Neutralization Titers in Immunosuppressed Patients with Chronic Inflammatory Disease

Immunological Complications of Medical Therapy Poster

9:00AM-10:30AM: Abstract Number: 0829

Adult Onset Still’s Disease: A Retrospective Study of Objective Manifestations and Outcomes

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-10:30AM: Abstract Number: 0922

Alteration of the Cardiometabolic and Cardiovascular Proteome in Rheumatoid Arthritis. Modulation by Methotrexate and Tofacitinib

RA – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 0621

Altered Immunological Circadian Rhythms and the Effect of Treatment with Glucocorticoids on Circadian Rhythms of Immune Cells in Patients with Rheumatoid Arthritis: Bring Back the Rhythm

RA – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0604

Altered Metabolic State in Myeloid Precursors and Mature Cells Within Rheumatoid Arthritis

RA – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0598

An Arthritogenic Strain of Subdoligranulum Specifically Detectable in the Feces of Individuals At-risk for and with Rheumatoid Arthritis Is Bound by ACPA and Stimulates Th17 Cell Activation in Those with Rheumatoid Arthritis

RA – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0683

ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases: Clinical and Serological Characteristics, Results from the APS ACTION Clinical Database and Repository

Antiphospholipid Syndrome Poster

9:00AM-10:30AM: Abstract Number: 1073

Analysis of Clinical Outcomes in ANCA-associated Vasculitis Treated with Rituximab: Eighty Years a Single Center Experience in Japan

Vasculitis – ANCA-Associated Poster II: Treatment Efficacy, Clinical Outcomes, Biomarkers

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].